Savient Pharmaceuticals Announces Abstract Related To KRYSTEXXA® Accepted For Presentation At ASN Kidney Week 2013

Savient Pharmaceuticals Announces Abstract Related To KRYSTEXXA® Accepted For
                     Presentation At ASN Kidney Week 2013

PR Newswire

BRIDGEWATER, N.J., Oct. 8, 2013

BRIDGEWATER, N.J., Oct.8, 2013 /PRNewswire/ --Savient Pharmaceuticals, Inc.
(NASDAQ: SVNT) announced today that an abstract related to KRYSTEXXA^®
(pegloticase) has been selected for poster presentation at the American
Society of Nephrology (ASN) Kidney Week 2013. The annual meeting will be held
November 5-10, 2013, in Atlanta, GA.

Savient's abstract, #FR-PO417, entitled "Pegloticase, a Recombinant Uricase
for the Treatment of Advanced Gout, Maintains Therapeutic Concentrations
During Dialysis" will be presented in a poster session titledDialysis:
Epidemiology, Outcomes, and Clinical Trials; Non-Cardiovascular I, on Friday,
November 8, 2013, from 10:00am to 12:00pm ET.

Savient Pharmaceuticals, a specialty biopharmaceutical company focused
on developing and commercializing KRYSTEXXA^®(pegloticase) for the treatment
of chronic gout in adult patients who do not respond to conventional therapy.
Savient has exclusively licensed worldwide rights to the technology related to
KRYSTEXXA and its uses fromDuke University("Duke") andMountain View
Pharmaceuticals, Inc.("MVP").Dukedeveloped the recombinant uricase enzyme
and MVP developed the PEGylation technology used in the manufacture of
KRYSTEXXA. MVP andDukehave been granted U.S. and foreign patents disclosing
and claiming the licensed technology and, in addition, Savient owns or co-owns
U.S. and foreign patents and patent applications, which collectively form a
broad portfolio of patents covering the composition, manufacture and methods
of use and administration of KRYSTEXXA. In the U.S., Savient also supplies
Oxandrin^®(oxandrolone tablets, USP) CIII and co-promotes
Kineret^®(anakinra) with Swedish Orphan Biovitrum AB (Sobi). For more
information, please visit the Company's website

Certain information in this press release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that are not
statements of historical fact should be considered forward-looking statements.
We often use words such as "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe," "may," "predict," "will," "would," "could,"
"should," "target" and similar expressions to identify forward-looking
statements. Actual results or events could differ materially from those
indicated in forward-looking statements as a result of risks and
uncertainties. For a discussion of some of the risks and important factors
that we believe could cause actual results or events to differ from the
forward-looking statements that we make, see the sections entitled "Risk
Factors" and "Management's Discussion and Analysis of Financial Condition and
Results of Operations" in our Quarterly Report on Form 10-Q for the quarter
endedJune 30, 2013. In addition, new risks and uncertainties emerge from time
to time, and it is not possible for the Company to predict or assess the
impact of every factor that may cause its actual results or events to differ
from those contained in any forward-looking statements.Accordingly, you
should not place undue reliance on any forward-looking statements contained in
this press release.Any forward-looking statements speak only as of the date
of this press release. We undertake no obligation to publicly update
forward-looking statements, whether as a result of new information, future
events or otherwise.



Savient Pharmaceuticals, Inc.
John P. Hamill
Co-President and Chief Financial Officer
(732) 418-9300

Burns McClellan
Caitlyn E. Murphy
(212) 213-0006

SOURCE Savient Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.